CCR
Os receptores de quimiocinas C-C (CCRs) são um grupo de GPCRs que respondem às quimiocinas, moléculas de sinalização que orientam a migração de células imunológicas para locais de inflamação ou infecção. Os CCRs desempenham papéis cruciais nas respostas imunológicas, inflamação e no desenvolvimento de várias doenças, incluindo distúrbios autoimunes e câncer. A modulação da atividade dos CCRs está sendo explorada como uma estratégia terapêutica para condições como artrite reumatoide, esclerose múltipla e infecção pelo HIV. Na CymitQuimica, oferecemos uma gama de moduladores de CCR de alta qualidade para apoiar sua pesquisa em imunologia, inflamação e desenvolvimento terapêutico.
Foram encontrados 136 produtos de "CCR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MLN-3897 TFA
<p>MLN-3897 TFA is a potent CCR1 antagonist that inhibits the binding of 125I-MIP-1α to THP-1 cell membranes.</p>Fórmula:C32H32ClF3N2O6Pureza:98.62%Cor e Forma:SolidPeso molecular:633.05Chemokine Inhibitor Library
<p>A unique collection of xnum chemokines or chemokine receptors targeted compounds for high throughput and high content screening;</p>Cor e Forma:Odour SolidCCR4 antagonist 3 hydrochloride
CAS:<p>Orally active CCR4 antagonist 3 hydrochloride with potent selectivity, IC50s: 22/50 nM; has antitumor properties.</p>Fórmula:C24H27Cl2N7O·xHClCor e Forma:SolidCHS-114
<p>CHS-114 (SRF-114) is a fully human IgG1 antibody targeting the (CCR8) receptor. It shows potential for research in head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can be referred to as HumanIgG1kappa, Isotype Control.</p>Cor e Forma:Odour LiquidGSK-3050002
<p>GSK-3050002 (HGS-1035) is a humanized IgG1 antibody that targets and binds to CCL20. It holds potential for inflammation research. For isotype control, refer to Human IgG1 kappa, Isotype Control.</p>Cor e Forma:Odour LiquidCafelkibart
<p>Cafelkibart is a chimeric IgG1κ monoclonal antibody targeting CCR8, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>Cor e Forma:Odour LiquidCCR6 antagonist 1
CAS:<p>CCR6 antagonist 1 blocks CCL20/CCR6, aiding autoimmune and IBD research.</p>Fórmula:C17H12F3NO2Pureza:99.83%Cor e Forma:SoildPeso molecular:319.28INCB 3284 dimesylate
CAS:<p>INCB 3284 dimesylate: oral CCR2 antagonist, blocks MCP-1/hCCR2 binding (IC50: 3.7 nM), potential in acute liver failure research.</p>Fórmula:C28H39F3N4O10S2Pureza:98%Cor e Forma:SolidPeso molecular:712.76Plozalizumab
CAS:<p>Plozalizumab (MLN-1202) is a humanized selective and potent anti-CCR2 antibody.Plozalizumab has antitumor activity.Plozalizumab is used in the study of</p>Pureza:96.4%Cor e Forma:LiquidPeso molecular:146.02 kDaINCB3344 R-isomer
<p>INCB3344 is a potent CCR2 antagonist. INCB3344 R-isomer is the R-isomer of INCB3344.</p>Fórmula:C29H34F3N3O6Pureza:98%Cor e Forma:SolidPeso molecular:577.59SQA1
CAS:<p>SQA1 is a derivative of a phthalamide (SQA) and acts as a CCR6 antagonist with a Kd of 250 nM, as well as a CXCR2 inhibitor. It occupies an intracellular pocket that overlaps with the G protein binding site, stabilizing the pocket's closed conformation.</p>Fórmula:C22H26N4O5Cor e Forma:SolidPeso molecular:426.47CCR4 antagonist 3
CAS:<p>Orally active CCR4 antagonist with piperidinyl-azetidine; IC50: 22 nM (calcium flux), 50 nM (CTX); antitumor effects.</p>Fórmula:C24H27Cl2N7OCor e Forma:SolidPeso molecular:500.43Zn-DPA-maytansinoid conjugate 1
<p>Zn-DPA-maytansinoid 1 targets checkpoints, shrinks tumors, and heats TME.</p>Fórmula:C115H145ClN18O31S2Zn2Cor e Forma:SolidPeso molecular:2505.83CAP-100
<p>CAP-100 is a monoclonal antibody targeting CCR7. It neutralizes the ligand binding site and signaling of CCR7. This compound effectively inhibits migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples induced by CCR7. CAP-100 can mediate potent tumor cell killing through host immune mechanisms and exhibits favorable toxicity profiles in related hematopoietic cell subsets. It is involved in research on antitumor activity and diseases like chronic lymphocytic leukemia (CLL).</p>Cor e Forma:Odour LiquidMet-RANTES,human,acetate
<p>Met-RANTES (human) acetate is the acetate salt form of Met-RANTES (human). It acts as an antagonist for CCR1 and CCR5 receptors. This compound inhibits the human chemokines MIP-1α and MIP-1β, with respective IC50 values of 5 and 2 nM. Additionally, Met-RANTES (human) acetate reduces bone destruction and alleviates adjuvant-induced arthritis (AIA) in rats.</p>Cor e Forma:Odour SolidCKLF1-C27 TFA
<p>CKLF1-C27 peptide activates ERK1/2 via CCR4, competes with CKLF1, promotes HUVEC growth, and has psoriasis research potential.</p>Fórmula:C153H244F3N39O39Cor e Forma:SolidPeso molecular:3310.8PF-232798
CAS:<p>PF-232798 is a second generation oral CCR5 antagonist with potent broad-spectrum anti-HIV-1 activity.</p>Fórmula:C29H40FN5O2Cor e Forma:SolidPeso molecular:509.66CCR6 antagonist 2
<p>CCR6 antagonist2 (Compound 20c) acts as a CCR6 antagonist with a Ki of 1.1 nM. It inhibits CCL20-induced calcium influx with an IC50 of 4.9 nM and suppresses the chemotactic migration of CCR6+ T cells with an IC50 of 190 nM.</p>Fórmula:C19H24N4O4Cor e Forma:SolidPeso molecular:372.42CCR8 antagonist 1
CAS:<p>CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.</p>Fórmula:C26H29N3O5SPureza:99.51%Cor e Forma:SolidPeso molecular:495.59WAY-639418
CAS:<p>WAY-639418 has potential anti-inflammatory and anti-HIV activity and can be used to study CCR5-mediated inflammatory and immunomodulatory diseases.</p>Fórmula:C17H16ClN5Pureza:99.62%Cor e Forma:SolidPeso molecular:325.8
